patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_190192 | REC_0013601 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.6 | 81 | female | 3 | 17 | 6.3 | 1 | alectinib 600 mg BID | 10.5 | false | MSI-H | 2026-03-15T05:36:00.452850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316221 | REC_0013602 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.3 | 72 | male | 3 | 5 | 6.9 | 7 | alectinib 600 mg BID | 8.7 | false | MSI-H | 2026-03-15T05:36:00.453222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994463 | REC_0013603 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 14 | 12.8 | 71 | female | 1 | 14 | 4.8 | 0 | osimertinib 80 mg daily | 27.1 | true | MSI-H | 2026-03-15T05:36:00.453579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373334 | REC_0013604 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.8 | 63 | male | 1 | 24 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:36:00.453906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423784 | REC_0013605 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 9.9 | 62 | female | 1 | 22 | 4.4 | 6 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:00.454198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641339 | REC_0013606 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 36 | 10.5 | 70 | female | 2 | 11 | 7.1 | 1 | sotorasib 960 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:36:00.454491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425581 | REC_0013607 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.5 | 71 | female | 2 | 12 | 6.1 | 4 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:36:00.454806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693906 | REC_0013608 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.6 | 61 | female | 0 | 0 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 7 | true | MSS | 2026-03-15T05:36:00.455126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355798 | REC_0013609 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17 | 66 | female | 0 | 15 | 6.8 | 5 | alectinib 600 mg BID | 10.5 | false | MSI-H | 2026-03-15T05:36:00.455444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280021 | REC_0013610 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.8 | 73 | female | 2 | 61 | 6.5 | 5 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:36:00.455732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482784 | REC_0013611 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10 | 72 | female | 2 | 19 | 6.2 | 1 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:00.456017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516813 | REC_0013612 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 37 | 10.4 | 65 | female | 0 | 29 | 9.2 | 4 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:36:00.456513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203077 | REC_0013613 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.4 | 76 | female | 0 | 30 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.4 | false | MSS | 2026-03-15T05:36:00.456826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475825 | REC_0013614 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 17.6 | 82 | male | 2 | 26 | 2.6 | 5 | pembrolizumab 200 mg q3w | 7 | true | MSI-H | 2026-03-15T05:36:00.457126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640362 | REC_0013615 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.6 | 59 | female | 0 | 13 | 4.1 | 5 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:00.457420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654478 | REC_0013616 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.4 | 52 | male | 0 | 15 | 7 | 1 | osimertinib 80 mg daily | 26.8 | true | MSS | 2026-03-15T05:36:00.457697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366170 | REC_0013617 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.3 | 81 | female | 1 | 17 | 5 | 7 | entrectinib 600 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:00.458003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652616 | REC_0013618 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 4.4 | 67 | female | 1 | 12 | 3.2 | 5 | alectinib 600 mg BID | 8.9 | false | MSS | 2026-03-15T05:36:00.458300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170509 | REC_0013619 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.2 | 69 | female | 1 | 65 | 3.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:36:00.458619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609350 | REC_0013620 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 22.3 | 64 | female | 0 | 16 | 7.3 | 5 | alectinib 600 mg BID | 12.6 | false | MSI-H | 2026-03-15T05:36:00.458950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237084 | REC_0013621 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 15.5 | 66 | female | 0 | 19 | 8.1 | 6 | pembrolizumab 200 mg q3w | 16 | false | MSI-H | 2026-03-15T05:36:00.459269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144807 | REC_0013622 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 4 | 67 | female | 0 | 18 | 4.9 | 5 | sotorasib 960 mg daily | 12 | true | MSS | 2026-03-15T05:36:00.459560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127505 | REC_0013623 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 10.8 | 56 | female | 0 | 12 | 6.3 | 0 | osimertinib 80 mg daily | 30.8 | false | MSI-H | 2026-03-15T05:36:00.459875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572808 | REC_0013624 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.6 | 67 | female | 1 | 10 | 4.4 | 2 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:36:00.460377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284701 | REC_0013625 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.5 | 62 | male | 1 | 14 | 6.2 | 3 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:36:00.460914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517124 | REC_0013626 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 15.4 | 65 | male | 1 | 8 | 6 | 1 | alectinib 600 mg BID | 10.1 | false | MSI-H | 2026-03-15T05:36:00.461315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164821 | REC_0013627 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.2 | 73 | female | 1 | 5 | 3.9 | 5 | alectinib 600 mg BID | 16.6 | true | MSI-H | 2026-03-15T05:36:00.461655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525651 | REC_0013628 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.6 | 71 | female | 1 | 13 | 3.8 | 4 | entrectinib 600 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:00.461992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310394 | REC_0013629 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.2 | 62 | male | 0 | 62 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:36:00.462309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276741 | REC_0013630 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 4 | 72 | female | 1 | 19 | 6.5 | 4 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:36:00.462640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322861 | REC_0013631 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.2 | 77 | male | 2 | 7 | 4.8 | 7 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:00.462974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362086 | REC_0013632 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 8.7 | 75 | female | 2 | 24 | 3.9 | 2 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:36:00.463293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912172 | REC_0013633 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.5 | 81 | male | 1 | 14 | 6.7 | 6 | osimertinib 80 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:36:00.463657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197488 | REC_0013634 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.6 | 67 | female | 1 | 53 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.4 | true | MSS | 2026-03-15T05:36:00.463984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801487 | REC_0013635 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 17 | 75 | female | 3 | 16 | 7.3 | 2 | sotorasib 960 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:36:00.464727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566028 | REC_0013636 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7 | 78 | female | 1 | 71 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:36:00.465115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102299 | REC_0013637 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 6.6 | 63 | male | 1 | 6 | 8 | 0 | sotorasib 960 mg daily | 30.1 | true | MSS | 2026-03-15T05:36:00.465481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200059 | REC_0013638 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.7 | 67 | male | 1 | 25 | 5.2 | 3 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.466061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245150 | REC_0013639 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 70 | female | 3 | 40 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:36:00.466492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519930 | REC_0013640 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.5 | 70 | female | 2 | 19 | 6.2 | 4 | alectinib 600 mg BID | 15.6 | false | MSI-H | 2026-03-15T05:36:00.466845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111567 | REC_0013641 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.3 | 90 | male | 1 | 15 | 6.6 | 1 | osimertinib 80 mg daily | 23.3 | true | MSS | 2026-03-15T05:36:00.467178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447092 | REC_0013642 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 16.1 | 63 | male | 1 | 28 | 4.8 | 1 | osimertinib 80 mg daily | 24.9 | true | MSI-H | 2026-03-15T05:36:00.467497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265211 | REC_0013643 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.7 | 68 | female | 0 | 13 | 7.8 | 5 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:36:00.467830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573361 | REC_0013644 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 9.1 | 79 | female | 1 | 6 | 5.8 | 6 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:36:00.468223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409961 | REC_0013645 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.1 | 64 | male | 1 | 9 | 5.1 | 1 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.468607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776084 | REC_0013646 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.6 | 66 | female | 1 | 20 | 5.7 | 7 | entrectinib 600 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:36:00.468952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376920 | REC_0013647 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11 | 72 | male | 2 | 16 | 5.2 | 5 | alectinib 600 mg BID | 7.3 | true | MSI-H | 2026-03-15T05:36:00.470354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688179 | REC_0013648 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 18 | 14.9 | 71 | female | 2 | 14 | 4.3 | 0 | sotorasib 960 mg daily | 38.8 | true | MSI-H | 2026-03-15T05:36:00.470769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846852 | REC_0013649 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.1 | 72 | female | 1 | 17 | 6 | 6 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:36:00.472390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696832 | REC_0013650 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 11.1 | 59 | male | 1 | 17 | 5.7 | 8 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:00.472876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675790 | REC_0013651 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.3 | 84 | female | 2 | 11 | 6 | 7 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:00.473351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181593 | REC_0013652 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.1 | 68 | female | 1 | 8 | 6.9 | 8 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:00.473684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500146 | REC_0013653 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 18 | 60 | male | 1 | 7 | 5.8 | 5 | sotorasib 960 mg daily | 5.2 | true | MSS | 2026-03-15T05:36:00.474003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461262 | REC_0013654 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 21.3 | 86 | female | 1 | 14 | 3.6 | 7 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:36:00.474301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202509 | REC_0013655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 12.1 | 69 | female | 0 | 20 | 5.7 | 1 | osimertinib 80 mg daily | 20.3 | false | MSI-H | 2026-03-15T05:36:00.474598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956558 | REC_0013656 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.5 | 71 | female | 2 | 13 | 4.9 | 6 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:36:00.474894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746530 | REC_0013657 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 5 | 70 | female | 1 | 10 | 6.1 | 4 | pembrolizumab 200 mg q3w | 12.6 | true | MSS | 2026-03-15T05:36:00.475173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789023 | REC_0013658 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 16.2 | 68 | female | 1 | 15 | 5.7 | 1 | osimertinib 80 mg daily | 28 | false | MSI-H | 2026-03-15T05:36:00.475461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757656 | REC_0013659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 15.8 | 58 | female | 1 | 17 | 6.1 | 6 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:00.475747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359727 | REC_0013660 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7.9 | 73 | female | 1 | 2 | 6.9 | 5 | alectinib 600 mg BID | 4.5 | false | MSS | 2026-03-15T05:36:00.476024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412950 | REC_0013661 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 15 | 71 | female | 2 | 23 | 4.1 | 1 | osimertinib 80 mg daily | 5.8 | false | MSI-H | 2026-03-15T05:36:00.476421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941101 | REC_0013662 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.4 | 76 | male | 1 | 7 | 6 | 1 | pembrolizumab 200 mg q3w | 24 | false | MSS | 2026-03-15T05:36:00.476775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682925 | REC_0013663 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 13.3 | 63 | female | 0 | 14 | 4.7 | 1 | osimertinib 80 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:36:00.477094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165147 | REC_0013664 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.7 | 67 | male | 1 | 16 | 5.8 | 5 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:00.477561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616318 | REC_0013665 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.5 | 63 | female | 1 | 6 | 4.2 | 5 | sotorasib 960 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:00.477926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474697 | REC_0013666 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 17.9 | 63 | male | 0 | 18 | 5.4 | 1 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:00.478242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958681 | REC_0013667 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 16 | 55 | male | 1 | 14 | 4.9 | 0 | sotorasib 960 mg daily | 51.3 | true | MSI-H | 2026-03-15T05:36:00.478545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651724 | REC_0013668 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.4 | 66 | female | 1 | 22 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:36:00.478852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394958 | REC_0013669 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.9 | 57 | female | 0 | 20 | 7.4 | 6 | sotorasib 960 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:36:00.479177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502157 | REC_0013670 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.6 | 56 | male | 1 | 3 | 7.1 | 8 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:36:00.479459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623624 | REC_0013671 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11.7 | 71 | male | 1 | 9 | 7.6 | 5 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:36:00.479784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801467 | REC_0013672 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 10.2 | 70 | female | 2 | 23 | 6.1 | 8 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:00.480146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556755 | REC_0013673 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 12.7 | 68 | female | 1 | 19 | 4.5 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:36:00.480545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273378 | REC_0013674 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.1 | 64 | male | 1 | 58 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 19.4 | true | MSS | 2026-03-15T05:36:00.480926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341701 | REC_0013675 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10.9 | 57 | female | 1 | 13 | 3.5 | 2 | osimertinib 80 mg daily | 22.4 | false | MSS | 2026-03-15T05:36:00.481281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673264 | REC_0013676 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13.7 | 66 | male | 0 | 12 | 6.1 | 4 | sotorasib 960 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:36:00.481833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747904 | REC_0013677 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 36 | 10.7 | 72 | female | 1 | 17 | 5.2 | 1 | alectinib 600 mg BID | 8.1 | false | MSS | 2026-03-15T05:36:00.482629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677103 | REC_0013678 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 36 | 7.5 | 63 | female | 1 | 20 | 5.1 | 7 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:36:00.483616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925174 | REC_0013679 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.8 | 76 | female | 1 | 31 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:36:00.484432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971604 | REC_0013680 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 3.4 | 67 | female | 0 | 7 | 4.8 | 8 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:36:00.485061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366807 | REC_0013681 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.5 | 72 | female | 1 | 22 | 3.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:36:00.485447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291445 | REC_0013682 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.2 | 68 | female | 1 | 55 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 9 | true | MSS | 2026-03-15T05:36:00.485780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969404 | REC_0013683 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 4.8 | 66 | male | 1 | 5 | 5.6 | 0 | osimertinib 80 mg daily | 37.3 | true | MSS | 2026-03-15T05:36:00.486095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707697 | REC_0013684 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 4.6 | 76 | female | 3 | 25 | 9.5 | 1 | pembrolizumab 200 mg q3w | 14.4 | false | MSS | 2026-03-15T05:36:00.486391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143681 | REC_0013685 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 15.8 | 67 | female | 1 | 24 | 3.7 | 5 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:00.486711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297012 | REC_0013686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 7.8 | 87 | female | 1 | 11 | 6.8 | 7 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:00.487023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613819 | REC_0013687 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 17.1 | 60 | female | 0 | 13 | 4 | 2 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:36:00.487333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104033 | REC_0013688 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 8 | 58 | female | 1 | 35 | 7.1 | 7 | pembrolizumab 200 mg q3w | 6.7 | false | MSS | 2026-03-15T05:36:00.487641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816527 | REC_0013689 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 17.5 | 69 | male | 1 | 11 | 4.1 | 1 | entrectinib 600 mg daily | 5.3 | true | MSI-H | 2026-03-15T05:36:00.487975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842958 | REC_0013690 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.1 | 74 | female | 2 | 18 | 6 | 1 | alectinib 600 mg BID | 20.1 | true | MSI-H | 2026-03-15T05:36:00.488879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721240 | REC_0013691 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.3 | 65 | female | 0 | 8 | 5.9 | 1 | sotorasib 960 mg daily | 19.8 | false | MSS | 2026-03-15T05:36:00.489337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206726 | REC_0013692 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 14.8 | 61 | male | 1 | 14 | 6.9 | 1 | osimertinib 80 mg daily | 27.1 | false | MSI-H | 2026-03-15T05:36:00.489719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469356 | REC_0013693 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 9.7 | 65 | female | 0 | 20 | 2.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:36:00.490086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819189 | REC_0013694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 19.4 | 62 | female | 0 | 20 | 5.6 | 1 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:36:00.490460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898062 | REC_0013695 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 6.7 | 67 | female | 1 | 25 | 5.5 | 3 | sotorasib 960 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:00.490805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572145 | REC_0013696 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 3.9 | 66 | female | 0 | 19 | 6.1 | 1 | osimertinib 80 mg daily | 25.5 | false | MSS | 2026-03-15T05:36:00.491138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252687 | REC_0013697 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 22.2 | 63 | male | 0 | 24 | 5.8 | 6 | entrectinib 600 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:00.491478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697618 | REC_0013698 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 15.4 | 77 | male | 1 | 20 | 7 | 0 | entrectinib 600 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:00.491833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512952 | REC_0013699 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.9 | 70 | female | 1 | 2 | 5.3 | 3 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.492217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952599 | REC_0013700 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.8 | 73 | female | 2 | 7 | 7.2 | 6 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:36:00.492563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.